FBXL22: A Potential Drug Target and Biomarker (G283807)

Target Name: FBXL22

NCBI ID: G283807

FBXL22

FBXL22: A Potential Drug Target and Biomarker

The F-box and leucine rich repeat (LRR) domain is a highly conserved protein that can be found in a variety of organisms, including humans. One of the functions of this domain is to interact with various signaling pathways, including the PI3K/Akt signaling pathway. FBXL22, a protein with this domain, has been identified as a potential drug target and biomarker for various diseases.

The FBXL22 protein is a 22 kDa protein that is expressed in various tissues and organs, including the brain, heart, liver, and muscle. It is characterized by an N-terminal F-box domain and a C-terminal LRR domain. The F-box domain is a common protein structural domain that is involved in various signaling pathways, including the regulation of protein stability and cell signaling. The LRR domain is a specific protein structural domain that is known for its role in protein-protein interactions and is involved in the regulation of protein stability.

FBXL22 has been shown to play a role in various signaling pathways, including the PI3K/Akt signaling pathway. This pathway is involved in the regulation of cell proliferation, survival, and angiogenesis, and is a target for many diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. FBXL22 has been shown to interact with the protein PDGFR-尾, which is a member of the PI3K/Akt signaling pathway. This interaction suggests that FBXL22 may be a negative regulator of the PI3K/Akt signaling pathway.

FBXL22 has also been shown to be involved in the regulation of cellular processes that are important for cancer progression. For example, studies have shown that FBXL22 is involved in the regulation of the angiogenic factors, which are factors that promote cancer cell growth and survival. Additionally, studies have shown that FBXL22 is involved in the regulation of the pro-inflammatory pathway, which is involved in the regulation of inflammation and has been implicated in cancer progression.

FBXL22 has also been shown to be involved in the regulation of cellular processes that are important for neurodegenerative diseases. For example, studies have shown that FBXL22 is involved in the regulation of the neurotransmitter clearance pathway, which is involved in the regulation of neurotransmitter levels in the brain and is implicated in the development of neurodegenerative diseases. Additionally, studies have shown that FBXL22 is involved in the regulation of the stress response pathway, which is involved in the regulation of stress responses and is implicated in the development of neurodegenerative diseases.

FBXL22 has also been shown to be involved in the regulation of cellular processes that are important for cardiovascular diseases. For example, studies have shown that FBXL22 is involved in the regulation of the angiogenesis pathway, which is involved in the regulation of blood vessel formation and is implicated in the development of cardiovascular diseases. Additionally, studies have shown that FBXL22 is involved in the regulation of the signaling pathway that is involved in the regulation of cellular signaling, which is involved in the regulation of cellular signaling and is implicated in the development of cardiovascular diseases.

In conclusion, FBXL22 is a protein that is involved in various signaling pathways and has been shown to play a role in the regulation of cellular processes that are important for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Therefore, FBXL22 is a potential drug target and biomarker for these diseases. Further research is needed to fully understand the role of FBXL22 in these processes and to develop effective treatments for these diseases.

Protein Name: F-box And Leucine Rich Repeat Protein 22

Functions: Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex. Promotes ubiquitination of sarcomeric proteins alpha-actinin-2 (ACTN2) and filamin-C (FLNC)

The "FBXL22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXL22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets